A COPD Patient Who Developed Pulmonary Fibrosis Following COVID-19: A Case Study
DOI:
https://doi.org/10.12974/2312-5470.2021.07.06Keywords:
SARS-Cov-2 pneumonia, Covid-19 related pulmonary fibrosis, Respiratory functional analysis, Steroid, Acetyl-cysteineAbstract
The new virus called severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) causing Coronavirus disease 2019 (COVID-19) has spread to several countries and caused the current pandemic. Different types of clinical manifestations are associated with that infection.
Some drugs have been approved such as anti-viral agents but the use of corticosteroids is controversial. Pulmonary fibrosis is a frequent consequence of Covid-19 that may requires a special attention and a specific follow up.
Herein we report a case of a 68-years-old patient affected by SARS-Cov-2 infection complicated by pulmonary fibrosis who healed from Covid-19 infection after a total inpatient stay of 12 days by with remdesivir treatment. The patient presented a chest fibrosis picture at the discharge that went on at 10 days check with a decline of respiratory functional parameters. For this reason a combined treatment with high dose prednisone and N-acetyl-cysteine was started.
The patients benefited from high dose corticosteroids plus N-acetyl-cysteine leading to a clinical and functional improvement. Indeed, the patient underwent a chest CT-scan and spirometry at one month check after the beginning of the treatment.
Notably both the radiological pattern of fibrosis and respiratory function improved after treatment with prednisone 50 mg a day for 15 days followed by 25 mg for additional 15 days and N-acetylcisteine 600 mg twice a day.
References
Zella D, Giovanetti M, Cella E, Borsetti A, Ciotti M, Ceccarelli G, D'Ettorre G, Pezzuto A, Tambone V, Campanozzi L, Magheri M, Unali F, Bianchi M, Benedetti F, Pascarella S, Angeletti S, Ciccozzi M. The importance of genomic analysis in cracking the coronavirus pandemic. Expert Rev Mol Diagn. 2021; 21(6): 547-562. Epub 2021 Apr 28. PMID: 33849359; PMCID: PMC8095159. https://doi.org/10.1080/14737159.2021.1917998
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Tammaro A, Chello C, Sernicola A, Magri F, Adebanjo GAR, Parisella FR, et al. Necrotic acral lesions and lung failure in a fatal case of COVID-19.Australas J Dermatol 2020 Jul 16: 10.1111/ajd.13400. https://doi.org/10.1111/ajd.13400
Enoki Y, Igarashi Y, Watabe Y, Honma K, Suzuki Y, Hayashi Y, et al. Remdesivir for the treatment of coronavirus COVID- 19: a meta-analysis of randomised controlled trials. J Glob Antimicrob Resist 2020; 8: S2213-7165(20):30308-8.
Laszlo G. Standardization of lung function testing: helpful guidance from the ATS/ERS Task Force. Thorax 2006; 61(9): 744-6. https://doi.org/10.1136/thx.2006.061648
Xie C, Lu J, Wu D, Zhang L, Zhao H, Rao B, Yang Z. False negative rate of COVID-19 is eliminated by using nasal swab test. Travel Med Infect Dis 2020 Apr 11:101668. https://doi.org/10.1016/j.tmaid.2020.101668
Zuin R, Palamidese A, Negrin R, Catozzo L, Scarda A, Balbinot M. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.Clin Drug Investig 2005; 25(6): 401-8. https://doi.org/10.2165/00044011-200525060-00005
Pezzuto A, Tammaro A, Tonini G, Ciccozzi M. COPD influences survival in patients affected by COVID-19, comparison between subjects admitted to an internal medicine unit, and subjects admitted to an intensive care unit: An Italian experience J Med Virol 2020 Oct 7:10.1002/jmv.26585. https://doi.org/10.1002/jmv.26585
Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients. J Infect 2020 Mar 27. pii: S0163-4453(20)30116-X.
Zou H, Li SQ. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention. Acta Pharmacol Sin 2020; 13: 1-3.
Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000; 162(1): 225-31. https://doi.org/10.1164/ajrccm.162.1.9903129
Meyer A, Buhl R, Magnussen H The effect of oral Nacetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7(3): 431-6. https://doi.org/10.1183/09031936.94.07030431
Feng F, Zhang J, Wang Z, Wu Q, Zhou X. Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis. Exp Ther Med 2019; 18(1): 802-816. https://doi.org/10.3892/etm.2019.7579
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De Vuyst P, van den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M; IFENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005; 353(21): 2229-42. https://doi.org/10.1056/NEJMoa042976
Lechowicz K, Drożdżal S, Machaj F, Rosik J, Szostak B, Zegan-Barańska B, Biernawska J, Dabrowski W, Rotter I, Kotfis K. COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 .Infection. J Clin Med 2020; 9(6): 1917. https://doi.org/10.3390/jcm9061917
George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med 2020; 8(8): 807-15. https://doi.org/10.1016/S2213-2600(20)30225-3
Lechowicz K, Drożdżal S, Machaj F, Rosik J , Szostak B , Zegan-Barańska M , Biernawska J, Dabrowski W , Rotter I, KotfisK .COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection J Clin Med 2020; 9(6). https://doi.org/10.3390/jcm9061917
Silva P, Felix N, Silva PL, Robba C, Battaglini D, Pelosi P et al. Pros and cons of corticosteroid therapy for COVID-19 patients. Respir Physiol Neurobiol 2020; 280: 103492 https://doi.org/10.1016/j.resp.2020.103492
Van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM. Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care 2020 14; 24(1): 696. https://doi.org/10.1186/s13054-020-03400-9
Li H, Liu C, HSU T, Lin J, Hsu J, Li A, Yeh Y, hung S, Hsu H. Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19. Part Fibre Toxicol 2021; 18(1): 11. https://doi.org/10.1186/s12989-021-00404-3
Campi I, Gennari L, Merlotti D, Mingiano C, Frosali A, Giovanelli L, Torlasco C, Pengo MF, Heilbron F, Soranna D, Zambon A, Di Stefano M, Aresta C, Bonomi M, Cangiano B, Favero V, Fatti L, Perego GB, Chiodini I, Parati G, Persani L. Vitamin D and COVID-19 severity and related mortality: a prospective study in Italy. BMC Infect Dis. 2021; 21(1): 566. PMID: 34126960; PMCID: PMC8200788. https://doi.org/10.1186/s12879-021-06281-7
Aranow C. Vitamin D and the immune system. J Investig Med 2011; 59(6): 881-6. PMID: 21527855; PMCID: PMC3166406. https://doi.org/10.2310/JIM.0b013e31821b8755
